NCM
ITCI

Nantahala Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Nantahala Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-174,461
Closed -$4.48M – 125
2020
Q3 		$4.48M Buy
+174,461
New +$3.98M 0.14% 86

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nantahala Capital Management's ITCI Position: Q4 2020 in Review

Nantahala Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2020, closing a stake of 174,461 shares — an estimated $4.48M sold.

Nantahala Capital Management first reported a position in ITCI in Q3 2020 and held it in 1 quarter. The position peaked at $4.48M in Q3 2020. 178 funds tracked by Wall St. Rank hold ITCI as of Q4 2020.

  • Nantahala Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2020 after selling out during the quarter.
  • Nantahala Capital Management sold 174,461 Intra-Cellular Therapies Inc. shares in Q4 2020, an estimated $4.48M.
  • Nantahala Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2020 and held it in 1 quarter.
  • Nantahala Capital Management's Intra-Cellular Therapies Inc. position peaked at $4.48M in Q3 2020.
  • 178 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2020.

Based on Nantahala Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.